Absorption, metabolism, and excretion of [¹⁴C]YY-20394, a highly selective PI3K-Delta inhibitor in humans

References

• Ahmad S, Abu-Eid R, Shrimali R, Webb M, Verma V, Doroodchi A, Berrong Z, Samara R, Rodriguez PC, Mkrtichyan M, et al. 2017. Differential PI3Kδ signaling in CD4+ T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Cancer Res. 77(8):1892–1904.
   PubMed Web of Science ®Google Scholar
• Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, Saki N. 2015. Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci. 72(12):2337–2347.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Beijnen JH, Schellens JHM. 2006. Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet. 45(1):33–58.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Keam SJ. 2021. Umbralisib: first approval. Drugs. 81(7):857–866.
   PubMed Web of Science ®Google Scholar
• FDA US 2020. Safety testing of drug metabolites guidance for industry. [accessed 2020 30 April 2020]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites.
   Google Scholar
• Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. 2017. The PI3K pathway in human disease. Cell. 170(4):605–635.
   PubMed Web of Science ®Google Scholar
• Frustaci AM, Tedeschi A, Deodato M, Zamprogna G, Cairoli R, Montillo M. 2020. Duvelisib for the treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother. 21(11):1299–1309.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, et al. 2014. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• Gerisch M, Schwarz T, Lang D, Rohde G, Reif S, Genvresse I, Reschke S, van der Mey D, Granvil C. 2017. Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers. Cancer Chemother Pharmacol. 80(3):535–544.
   PubMed Web of Science ®Google Scholar
• Hazenberg MP, Herder WWd, Visser TJ. 1988. Hydrolysis of iodothyronine conjugates by intestinal bacteria. FEMS Microbiol Rev. 4(1):9–16.
   PubMed Web of Science ®Google Scholar
• Hewett YG, Uprety D, Shah BK. 2016. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies. J Oncol Pharm Pract. 22(2):284–288.
   PubMed Web of Science ®Google Scholar
• Hillmann P, Fabbro D. 2019. PI3K/mTOR pathway inhibition: opportunities in oncology and rare genetic diseases. IJMS. 20(22):5792.
   Web of Science ®Google Scholar
• Jin J, Cen H, Zhou K, Xu X, Li F, Wu T, Yang H, Wang Z, Li Z, Qiu L, et al. 2021. A phase Ib study of a PI3Kδ inhibitor linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma. JCO. 39(15_suppl):7531–7531.
   Web of Science ®Google Scholar
• Katsuya H, Cook LBM, Rowan AG, Satou Y, Taylor GP, Bangham CRM. 2018. Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma. Biomark Res. 6:24.
   PubMed Web of Science ®Google Scholar
• Kim DH, Jin YH. 2001. Intestinal bacterial beta-glucuronidase activity of patients with colon cancer. Arch Pharm Res. 24(6):564–567.
   PubMed Web of Science ®Google Scholar
• Krause G, Hassenruck F, Hallek M. 2018. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 12:2577–2590.
   PubMed Web of Science ®Google Scholar
• McGurk KA, Brierley CH, Burchell B. 1998. Drug glucuronidation by human renal UDP-glucuronosyltransferases [Article. Biochem Pharmacol. 55(7):1005–1012.
   PubMed Web of Science ®Google Scholar
• Penner N, Klunk LJ, Prakash C. 2009. Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos. 30(4):185–203.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. 2014. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:64.
   PubMedGoogle Scholar
• Qi JY, Song YQ, Jiang B, Li JY, Tu MF, Ping LY, Li ZJ, Xu W, Zhu HY, Zhu J, et al. 2018. Preliminary results from a Phase I, first-in-human study of YY-20394, a highly selective and highly potent PI3Kδ Inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 132(Supplement 1):5332–5332.
   Web of Science ®Google Scholar
• Qiu LG, Qi JY, Song YQ, Jiang B, Tu MF, Ping LY, Li ZJ, Zhu J, Xu YY, Bao HY, et al. 2019. A phase I study of a selective PI3K delta inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies. J Clin Oncol. 37(15):7563.
   Web of Science ®Google Scholar
• Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, Manns MP. 2000. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem. 275(46):36164–36171.
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Nguyen N, Manns MP, Tukey RH. 1999. UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology. 116(1):149–160.
   PubMed Web of Science ®Google Scholar
• Tian J, Lei P, He Y, Zhang N, Ge X, Luo L, Yan S, Diao X. 2021. Absorption, distribution, metabolism, and excretion of [14C]NBP (3-n-butylphthalide) in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 1181:122915.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. 2010. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 11(5):329–341.
   PubMed Web of Science ®Google Scholar
• Yang QS, Modi P, Newcomb T, Queva C, Gandhi V. 2015. Idelalisib: first-in-class PI3K Delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 21(7):1537–1542.
   PubMed Web of Science ®Google Scholar
• Zheng YD, Zhang H, Zhan Y, Bian YC, Ma S, Gan HX, Lai XJ, Liu YQ, Gong YC, Liu XF, et al. 2021. Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. Acta Pharmacol Sin. 42(9):1535–1546.
   PubMed Web of Science ®Google Scholar